Cargando…

Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis

Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide tr...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Chih-Huang, Zhang, Jintao, Baylink, David J., Wang, Xiaohua, Goparaju, Naga Bharani, Xu, Yi, Wasnik, Samiksha, Cheng, Yanmei, Berumen, Edmundo Carreon, Qin, Xuezhong, Lau, Kin-Hing William, Tang, Xiaolei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Federation of American Societies for Experimental Biology 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471518/
https://www.ncbi.nlm.nih.gov/pubmed/28363955
http://dx.doi.org/10.1096/fj.201601243R
_version_ 1783243962359742464
author Li, Chih-Huang
Zhang, Jintao
Baylink, David J.
Wang, Xiaohua
Goparaju, Naga Bharani
Xu, Yi
Wasnik, Samiksha
Cheng, Yanmei
Berumen, Edmundo Carreon
Qin, Xuezhong
Lau, Kin-Hing William
Tang, Xiaolei
author_facet Li, Chih-Huang
Zhang, Jintao
Baylink, David J.
Wang, Xiaohua
Goparaju, Naga Bharani
Xu, Yi
Wasnik, Samiksha
Cheng, Yanmei
Berumen, Edmundo Carreon
Qin, Xuezhong
Lau, Kin-Hing William
Tang, Xiaolei
author_sort Li, Chih-Huang
collection PubMed
description Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide transient effects and require frequent administration, which further increases the chance to compromise immunity. In this regard, myelin-specific therapy may provide the desired specificity and a long-lasting therapeutic effect by inducing myelin-specific regulatory T (T(reg)) cells. Tolerogenic dendritic cells (TolDCs) are one such therapy. However, ex vivo generated TolDCs may be converted into immunogenic DCs in a proinflammatory environment. In this study, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence without the in vivo conversion concern. We showed that immunization with DCs, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral lymphoid tissues, induced T(reg) cells. In addition, such engineered DCs, when pulsed with a myelin antigen, led to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease suppression depended on forkhead-box-protein-P3(foxp3)(+) T(reg) cells. Our data support a novel concept that immunogenic DCs can be engineered for myelin-specific therapy for MS.—Li, C.-H., Zhang, J., Baylink, D. J., Wang, X., Goparaju, N. B., Xu, Y., Wasnik, S., Cheng, Y., Berumen, E. C., Qin, X., Lau, K.-H. W., Tang, X. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis.
format Online
Article
Text
id pubmed-5471518
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Federation of American Societies for Experimental Biology
record_format MEDLINE/PubMed
spelling pubmed-54715182017-06-21 Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis Li, Chih-Huang Zhang, Jintao Baylink, David J. Wang, Xiaohua Goparaju, Naga Bharani Xu, Yi Wasnik, Samiksha Cheng, Yanmei Berumen, Edmundo Carreon Qin, Xuezhong Lau, Kin-Hing William Tang, Xiaolei FASEB J Research Multiple sclerosis (MS) is caused by immune-mediated damage of myelin sheath. Current therapies aim to block such immune responses. However, this blocking is not sufficiently specific and hence compromises immunity, leading to severe side effects. In addition, blocking medications usually provide transient effects and require frequent administration, which further increases the chance to compromise immunity. In this regard, myelin-specific therapy may provide the desired specificity and a long-lasting therapeutic effect by inducing myelin-specific regulatory T (T(reg)) cells. Tolerogenic dendritic cells (TolDCs) are one such therapy. However, ex vivo generated TolDCs may be converted into immunogenic DCs in a proinflammatory environment. In this study, we identified a potential novel myelin-specific therapy that works with immunogenic DCs, hence without the in vivo conversion concern. We showed that immunization with DCs, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase for de novo synthesis of a focally high 1,25-dihydroxyvitamin D concentration in the peripheral lymphoid tissues, induced T(reg) cells. In addition, such engineered DCs, when pulsed with a myelin antigen, led to myelin-specific suppression of ongoing experimental allergic encephalomyelitis (an MS animal model), and the disease suppression depended on forkhead-box-protein-P3(foxp3)(+) T(reg) cells. Our data support a novel concept that immunogenic DCs can be engineered for myelin-specific therapy for MS.—Li, C.-H., Zhang, J., Baylink, D. J., Wang, X., Goparaju, N. B., Xu, Y., Wasnik, S., Cheng, Y., Berumen, E. C., Qin, X., Lau, K.-H. W., Tang, X. Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis. Federation of American Societies for Experimental Biology 2017-07 2017-03-31 /pmc/articles/PMC5471518/ /pubmed/28363955 http://dx.doi.org/10.1096/fj.201601243R Text en © The Author(s) http://creativecommons.org/licenses/by/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution 4.0 International (CC BY 4.0) (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Li, Chih-Huang
Zhang, Jintao
Baylink, David J.
Wang, Xiaohua
Goparaju, Naga Bharani
Xu, Yi
Wasnik, Samiksha
Cheng, Yanmei
Berumen, Edmundo Carreon
Qin, Xuezhong
Lau, Kin-Hing William
Tang, Xiaolei
Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title_full Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title_fullStr Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title_full_unstemmed Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title_short Dendritic cells, engineered to overexpress 25-hydroxyvitamin D 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
title_sort dendritic cells, engineered to overexpress 25-hydroxyvitamin d 1α-hydroxylase and pulsed with a myelin antigen, provide myelin-specific suppression of ongoing experimental allergic encephalomyelitis
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5471518/
https://www.ncbi.nlm.nih.gov/pubmed/28363955
http://dx.doi.org/10.1096/fj.201601243R
work_keys_str_mv AT lichihhuang dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT zhangjintao dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT baylinkdavidj dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT wangxiaohua dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT goparajunagabharani dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT xuyi dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT wasniksamiksha dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT chengyanmei dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT berumenedmundocarreon dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT qinxuezhong dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT laukinhingwilliam dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis
AT tangxiaolei dendriticcellsengineeredtooverexpress25hydroxyvitamind1ahydroxylaseandpulsedwithamyelinantigenprovidemyelinspecificsuppressionofongoingexperimentalallergicencephalomyelitis